NeuroDerm Overview

  • Year Founded
  • 2003

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 173

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $1.1B

NeuroDerm General Information

Description

Operator of a clinical-stage pharmaceutical company intended to develop next-generation treatments for central nervous system disorders. The company specialzies in developing pharmaceutical drugs for central nervous system disorders and deficiencies in Parkinson's disease and central nervous system disorder treatments, thereby enabling patients to improve their quality of lives.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • 3 Haim Pekeris Street, Ruhrberg Science Building
  • Bell Entrance, 4th floor, Rabin Science Park
  • Rehovot 7670212
  • Israel
+972
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Vertical(s)
Corporate Office
  • 3 Haim Pekeris Street, Ruhrberg Science Building
  • Bell Entrance, 4th floor, Rabin Science Park
  • Rehovot 7670212
  • Israel
+972

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NeuroDerm Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
13. Merger/Acquisition 18-Oct-2017 $1.1B Completed Profitable
12. 2PO 28-Sep-2016 Completed Generating Revenue
11. Secondary Transaction - Open Market 15-Mar-2016 Completed Generating Revenue
10. PIPE 24-Jun-2015 Completed Clinical Trials - Phase 2
9. IPO 14-Nov-2014 Completed Generating Revenue
8. Later Stage VC 31-Aug-2014 Completed Generating Revenue
7. Grant 03-Jun-2013 Completed Generating Revenue
6. Later Stage VC 16-Jul-2012 Completed Generating Revenue
5. Later Stage VC (Series A) 23-Jul-2011 $2.5M $3.1M Completed Generating Revenue
4. Grant 06-Oct-2010 $1M $600K Completed Generating Revenue
To view NeuroDerm’s complete valuation and funding history, request access »

NeuroDerm Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a clinical-stage pharmaceutical company intended to develop next-generation treatments for central nervous s
Drug Discovery
Rehovot, Israel
173 As of 2023

Boston, MA
 

San Carlos, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

NeuroDerm Competitors (36)

One of NeuroDerm’s 36 competitors is CervoMed, a Formerly VC-backed company based in Boston, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CervoMed Formerly VC-backed Boston, MA
CuraSen Venture Capital-Backed San Carlos, CA
Cytokinetics Formerly VC-backed South San Francisco, CA
Prilenia Venture Capital-Backed Naarden, Netherlands
Neurona Therapeutics Formerly VC-backed South San Francisco, CA
You’re viewing 5 of 36 competitors. Get the full list »

NeuroDerm Patents

NeuroDerm Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025253369-A1 Automatic cannula inserter with reusable and disposable parts Pending 04-Jun-2024
AU-2024250257-A1 Methods and compositions for reducing symptoms of parkinson's disease Pending 14-Apr-2023
EP-4694877-A1 Methods and compositions for reducing symptoms of parkinson's disease Pending 14-Apr-2023
US-12161612-B2 Methods and compositions for reducing symptoms of parkinson's disease Active 14-Apr-2023
US-20240342124-A1 Methods and compositions for reducing symptoms of parkinson's disease Active 14-Apr-2023 A61K31/195
To view NeuroDerm’s complete patent history, request access »

NeuroDerm Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NeuroDerm Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Ben-Gurion University of the Negev University Majority
Capital Point Venture Capital Minority
Elias Group Corporation Minority
Foresite Capital Growth/Expansion Minority
Ofakim Hi-Tech Ventures Accelerator/Incubator Minority
To view NeuroDerm’s complete investors history, request access »

NeuroDerm FAQs

  • When was NeuroDerm founded?

    NeuroDerm was founded in 2003.

  • Where is NeuroDerm headquartered?

    NeuroDerm is headquartered in Rehovot, Israel.

  • What is the size of NeuroDerm?

    NeuroDerm has 173 total employees.

  • What industry is NeuroDerm in?

    NeuroDerm’s primary industry is Drug Discovery.

  • Is NeuroDerm a private or public company?

    NeuroDerm is a Private company.

  • What is the current valuation of NeuroDerm?

    The current valuation of NeuroDerm is .

  • What is NeuroDerm’s current revenue?

    The current revenue for NeuroDerm is .

  • How much funding has NeuroDerm raised over time?

    NeuroDerm has raised $79.1M.

  • Who are NeuroDerm’s investors?

    Ben-Gurion University of the Negev, Capital Point, Elias Group, Foresite Capital, and Ofakim Hi-Tech Ventures have invested in NeuroDerm.

  • Who are NeuroDerm’s competitors?

    CervoMed, CuraSen, Cytokinetics, Prilenia, and Neurona Therapeutics are some of the 36 competitors of NeuroDerm.

  • When was NeuroDerm acquired?

    NeuroDerm was acquired on 18-Oct-2017.

  • Who acquired NeuroDerm?

    NeuroDerm was acquired by Tanabe Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process